NCH93 is a patient-derived meningioma cell line established from the first relapse of a WHO grade III meningioma. Tumour tissue was obtained during surgical resection from a 64 year old male patient.
Production details:
Patient-derived cell line established from human tumour tissue obtained during surgical resection and expanded in vitro.
Cat. #:
162305
Cancer types:
Brain cancer
Organism:
Human
Tissue:
Brain
Morphology:
Adherent
Growth properties:
Cells grow as adherent monolayer cultures under standard culture conditions at 37°C in a humidified incubator with 5% CO2. Medium is replaced twice per week.
Primary citation:
Jungwirth et al. 2021. Cancer Lett. 506:1-10. PMID: 33652084.
Growth medium:
DMEM (high glucose) supplemented with 10% fetal calf serum (FCS), 1% GlutaMAX, and 1% penicillin/streptomycin.
Subculture routine:
Cells are passaged at sub-confluent densities using 0.05% Trypsin-EDTA. After enzymatic detachment, trypsin is neutralised with serum-containing medium and cells are reseeded into fresh culture vessels. Passage number should be recorded.
Temperature:
37°C
References:
Yu et al. 2021. Cancers. 13(23):5898. PMID: 34885009.
Jungwirth et al. 2021. Cancers. 28:506:1-10, PMID: 33652084.
Jungwirth et al. 2019. Cancers. 11(4):545. PMID: 30991738.
Jungwirth et al. 2021. Cancer Lett. 506:1-10. PMID: 33652084.
Human buccal mucosa modeling; Permeability, absorption and metabolism studies of various substances and enzymatically labile drugs; Drug delivery studies
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
